CN103462987B - The application of epigallocatechin gallate (EGCG) stearate and one treat psoriatic pharmaceutical composition - Google Patents
The application of epigallocatechin gallate (EGCG) stearate and one treat psoriatic pharmaceutical composition Download PDFInfo
- Publication number
- CN103462987B CN103462987B CN201310362217.2A CN201310362217A CN103462987B CN 103462987 B CN103462987 B CN 103462987B CN 201310362217 A CN201310362217 A CN 201310362217A CN 103462987 B CN103462987 B CN 103462987B
- Authority
- CN
- China
- Prior art keywords
- egcg
- stearate
- epigallocatechin gallate
- gel
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The application and the one that the invention discloses epigallocatechin gallate (EGCG) stearate treat psoriatic pharmaceutical composition, belong to epigallocatechin gallate (EGCG) stearate technical field.Described epigallocatechin gallate (EGCG) stearate and the pharmaceutical composition containing epigallocatechin gallate (EGCG) stearate can be used for treating psoriasis.
Description
Technical field
The invention belongs to epigallocatechin gallate (EGCG) stearate technical field, the application and the one that are specifically related to epigallocatechin gallate (EGCG) stearate treat psoriatic pharmaceutical composition.
Background technology
Psoriasis (Psoriasis), is commonly called as psoriasis, is a kind of that determined by polygenic inheritance, that multi-environment factor stimulates induction dysimmune chronic inflammation proliferative skin disorders; Psoriatic main pathological change is epidermal keratinocytes overgrown and abnormal differentiation, parakeratosis, shortage granular layer, skin revitalization vascularization and inflammatory cell infiltration etc.Its clinical manifestation mainly illing skin produces the dry squama of multilamellar silvery white repeatedly, and be distributed with extensive wellability erythema and obvious petechia under squama, Most patients has pruritis.
Psoriasis etiology unknown, pathogenesis is very complicated and be not yet fully elucidated, and there is no the method for effecting a radical cure completely at present.High and the obstinate refractory of this sick sickness rate, existingly in the world has the psoriatic more than 6,000,000 more than 20,000,000, in China; This sick sickness rate is in continuing rising trend and the state of an illness more stubbornness in recent years, and easy recurrence often need be treated repeatedly; The indecency outward appearance of skin pruritus and skin lesion, not only have a strong impact on the healthy of patient, and bring heavy financial burden and psychological burden to patient and family thereof, patient feels more painful, quality of life is had a strong impact on, and this disease has become one of disease of World Health Organization (WHO) and dermatitis research field primary study and control.
At present, psoriatic Drug therapy, comprises system and the topical therapeutic of chemicals, Chinese medicine, biological preparation and use in conjunction thereof; Though existing medicine is many, conventional as all Shortcomings parts such as glucocorticoids such as tretinoin, dithranol, methotrexate, ciclosporin, Embrel and dexamethasone: therapeutic effect can only reach Short Term Clinical curative effect mostly, effectively can not extend the catabasis of patient, be difficult to Control in recurring, be more difficult to cure this disease; Most medicines have the untoward reaction of degree varies, and patient is difficult to tolerance [see " Inner mongolia medical journal " 2012,44(6): 707-719 " psoriatic therapeutic advance "]; And some drugs is expensive; From security consideration, local application is better than systematic treating.Therefore, screen from natural product and develop safety, efficient and the novel psoriasis medicine of economy is very significant work.
Folium Camelliae sinensis is to the protective effect of skin and act in ancient TCM books early on the books to treating for skin disease; tea polyphenols (GreenTeaPolyphenols; GTP) be the general name of Polyhydroxy phenol in Folium Camelliae sinensis; large quantity research shows; tea polyphenols toxic and side effects is little, has pharmacological action widely and excellent antioxygenic property.Bibliographical information tea polyphenols to effective therapeutical effect of Animal Models of Psoriasis [see " ExperimentalDermatology " 2007; 16:678 – 684. " Greenteapolyphenolinducescaspase14inepidermalkeratinocyt esviaMAPKpathwaysandreducespsoriasiformlesionsintheflaky skinmousemodel "], weak point is that tea polyphenols easily oxidizedly causes poor stability, fat-soluble difference causes permeable membrane ability weak, brings difficulty to its extensive use.
Fat-soluble tea polyphenol be researcher in order to overcome the above-mentioned deficiency of tea polyphenols, by its chemical modification, the high-grade aliphatic ester of the tea polyphenols developed is the mixture of an esterification of the corresponding component of tea polyphenols, class or polyester compound; Epigallocatechin gallate (EGCG) stearate (EpigallocatechinGallateStearates, EGCGS) be a kind of product of fat-soluble tea polyphenol, based on features such as its excellent safety, non-oxidizabilitys, at present, the epigallocatechin gallate (EGCG) stearate circulated in market is mainly used as the antioxidant of edible grease and food, has no application table nutgall catechin gallic acid ester stearate and treats psoriatic report.
Summary of the invention
The object of the invention is to solve the problem and provide one and can treat psoriatic epigallocatechin gallate (EGCG) stearate and a kind of pharmaceutical composition.
The technical solution adopted in the present invention is:
The application of epigallocatechin gallate (EGCG) stearate, described epigallocatechin gallate (EGCG) stearate can be used for treating psoriasis.
One treats psoriatic pharmaceutical composition, described pharmaceutical composition is grouped into by the one-tenth of following weight percentage ratio: epigallocatechin gallate (EGCG) stearate 0.1% ~ 15%, carbomer940 0.5% ~ 2%, triethanolamine 0.7% ~ 3%, laurocapram 0.5% ~ 2%, dehydrated alcohol 5% ~ 40%, propylene glycol 5% ~ 15%, glycerol 5% ~ 15%, ethyl hydroxybenzoate 0.01 ~ 0.5%, surplus is purified water.
The present invention has the following advantages:
Epigallocatechin gallate (EGCG) stearate and a kind of pharmaceutical composition being main component with epigallocatechin gallate (EGCG) stearate are used for the treatment of psoriasis by the present invention, cheap, employing dermal topical application approach easy to use, avoids the untoward reaction of psoriasis systematic treating; Result of the test shows simultaneously, and medicine of the present invention is little to animal skin acute toxicity, and safety is high, and psoriatic pathological state and symptom can be made significantly to improve or disappear, and therapeutic effect is good; The deficiency that existing curing psoriasis medicine poor stability, therapeutic effect are undesirable can be overcome, be suitable for being used as the psoriatic medicine for the treatment of, there is good development prospect.
Accompanying drawing explanation
Fig. 1 is the Normal group mouse tail skin biopsy figure that the embodiment of the present invention 9 provides;
Fig. 2 is the 1% epigallocatechin gallate (EGCG) stearate gel group coating that provides of the embodiment of the present invention 9 mouse tail skin biopsy figure after 60 days;
Fig. 3 is the tretinoin cream group coating that provides of the embodiment of the present invention 9 mouse tail skin biopsy figure after 60 days;
Fig. 4 is the Normal group Mice Auricle skin biopsy figure that the embodiment of the present invention 10 provides;
Fig. 5 is the rear Mice Auricle skin biopsy figure of Blank gel agent group modeling success that the embodiment of the present invention 10 provides;
Fig. 6 is the modeling success that provides of the embodiment of the present invention 10 and is coated with 1% epigallocatechin gallate (EGCG) stearate gel Mice Auricle skin biopsy figure after 30 days;
Fig. 7 is the modeling success that provides of the embodiment of the present invention 10 and painting tretinoin cream Mice Auricle skin biopsy figure after 30 days.
Detailed description of the invention
Below in conjunction with drawings and embodiments, the present invention is further detailed explanation.
Embodiment 1
0.2% epigallocatechin gallate (EGCG) stearate gel
Prescription forms:
Preparation method:
Each component is taken by recipe quantity precision; Get carbomer940 to be spread on and to boil and the purified water let cool is surperficial, swellingly to spend the night, obtain clear gel substrate, slowly add triethanolamine under stirring and make substrate pH value be 7, for subsequent use; Get epigallocatechin gallate (EGCG) stearate, ethyl hydroxybenzoate is dissolved in dehydrated alcohol; Above-mentioned solution is transferred in gel-type vehicle for subsequent use, mix homogeneously, stirs 1h at water-bath 80 DEG C, add propylene glycol, glycerol, laurocapram successively, mix homogeneously, add purified water to 1000.0g, stir, to obtain final product.
Embodiment 2
1% epigallocatechin gallate (EGCG) stearate gel
Prescription forms:
Preparation method:
Each component is taken by recipe quantity precision; Get carbomer940 to be spread on and to boil and the purified water let cool is surperficial, swellingly to spend the night, obtain clear gel substrate, slowly add triethanolamine under stirring and make substrate pH value be 7, for subsequent use; Get epigallocatechin gallate (EGCG) stearate, ethyl hydroxybenzoate is dissolved in dehydrated alcohol; Above-mentioned solution is transferred in gel-type vehicle for subsequent use, mix homogeneously, stirs 1h at water-bath 80 DEG C, add propylene glycol, glycerol, laurocapram successively, mix homogeneously, add purified water to 1000.0g, stir, to obtain final product.
Embodiment 3
5% epigallocatechin gallate (EGCG) stearate gel
Prescription forms:
Preparation method:
Each component is taken by recipe quantity precision; Get carbomer940 to be spread on and to boil and the purified water let cool is surperficial, swellingly to spend the night, obtain clear gel substrate, slowly add triethanolamine under stirring and make substrate pH value be 7, for subsequent use; Get epigallocatechin gallate (EGCG) stearate, ethyl hydroxybenzoate is dissolved in dehydrated alcohol; Above-mentioned solution is transferred in gel-type vehicle for subsequent use, mix homogeneously, stirs 1h at water-bath 80 DEG C, add propylene glycol, glycerol, laurocapram successively, mix homogeneously, add purified water to 1000.0g, stir, to obtain final product.
Embodiment 4
10% epigallocatechin gallate (EGCG) stearate gel
Prescription forms:
Preparation method:
Each component is taken by recipe quantity precision; Get carbomer940 to be spread on and to boil and the purified water let cool is surperficial, swellingly to spend the night, obtain clear gel substrate, slowly add triethanolamine under stirring and make substrate pH value be 7, for subsequent use; Get epigallocatechin gallate (EGCG) stearate, ethyl hydroxybenzoate is dissolved in dehydrated alcohol; Above-mentioned solution is transferred in gel-type vehicle for subsequent use, mix homogeneously, stirs 1h at water-bath 80 DEG C, add propylene glycol, glycerol, laurocapram successively, mix homogeneously, add purified water to 1000.0g, stir, to obtain final product.
Embodiment 5
15% epigallocatechin gallate (EGCG) stearate gel
Prescription forms:
Preparation method:
Each component is taken by recipe quantity precision; Get carbomer940 to be spread on and to boil and the purified water let cool is surperficial, swellingly to spend the night, obtain clear gel substrate, slowly add triethanolamine under stirring and make substrate pH value be 7, for subsequent use; Get epigallocatechin gallate (EGCG) stearate, ethyl hydroxybenzoate is dissolved in dehydrated alcohol; Above-mentioned solution is transferred in gel-type vehicle for subsequent use, mix homogeneously, stirs 1h at water-bath 80 DEG C, add propylene glycol, glycerol, laurocapram successively, mix homogeneously, add purified water to 1000.0g, stir, to obtain final product.
Embodiment 6
0% epigallocatechin gallate (EGCG) stearate gel (Blank gel agent)
Prescription forms:
Preparation method:
Each component is taken by recipe quantity precision; Get carbomer940 to be spread on and to boil and the purified water let cool is surperficial, swellingly to spend the night, obtain clear gel substrate, slowly add triethanolamine under stirring and make substrate pH value be 7, for subsequent use; Get ethyl hydroxybenzoate and be dissolved in dehydrated alcohol; Above-mentioned solution is transferred in gel-type vehicle for subsequent use, mix homogeneously, stirs 1h at water-bath 80 DEG C, add propylene glycol, glycerol, laurocapram successively, mix homogeneously, add purified water to 1000.0g, stir, to obtain final product.
Embodiment 7
The acute toxicity test of epigallocatechin gallate (EGCG) stearate gel rabbit damaged skin.
Get rabbit 16, male and female half and half, respectively at trunk back depilation 150cm
2, lose hair or feathers after 24 hours, confirm depilation place change without exception, to rub gently depilation place with 1 ﹟ emery paper, make it rubescent and liquid oozes out in a organized way, but with not hemorrhage for spending.Damaged skin rabbit is divided into 4 groups at random, often organizes 4, male and female half and half; One group of coating epigallocatechin gallate (EGCG) stearate Blank gel agent 5g/ rabbit, other three components does not apply the epigallocatechin gallate (EGCG) stearate gel 3g/ rabbit that concentration expressed in percentage by weight is 5.0%, 10.0%, 15.0%, coating place oilpaper and gauze are fixed, tested material is removed after 24 hours, observe every day and record reaction of animals and death toll, Continuous Observation 7 days, the timely postmortem of dead animal, has abnormal person to carry out tectology microscopy.
Result shows, and none is dead for 4 treated animals, and after coating, animal ordinary circumstance is good, movable with behavior without significant change, diet and feces normal.
Embodiment 8
The acute toxicity test of epigallocatechin gallate (EGCG) stearate gel rabbit intact skin.
Get rabbit 16, male and female half and half, except not preparing damaged skin, test medicine and test method are with the acute toxicity test of embodiment nine damaged skin.
Result shows, and none is dead for 4 treated animals, and after coating, animal ordinary circumstance is good, movable with behavior without significant change, diet and feces normal.
Embodiment 9
The impact that epigallocatechin gallate (EGCG) stearate gel is formed mouse tail scale granular layer of epidermis.
Get body weight 20 ± 2g Kunming kind healthy mice 60, be divided into 6 groups at random, i.e. Normal group, Blank gel agent group, three dose form nutgall catechin gallic acid ester stearate gels trial drug group (concentration is respectively 0.2%, 1.0%, 5.0%), tretinoin cream positive drug group (concentration is 0.025%), often organize 10, male and female half and half.Normal group is coating not, other is respectively organized evenly to be coated with respectively and gives corresponding medicine in mouse tail, 0.1g/ Mus, every twice-daily, successive administration 60 days, after last coating, 24h puts to death animal, get apart from root that to be about 1.5cm Mus tail back side skin one rectangular, fix by 10% formalin, paraffin embedding, section, HE dyes; Under optical microscope, observe scale epidermis one by one to each specimen formed with or without granular layer, all scale epidermises have the granular cell person embarked on journey continuously, be considered as the scale that granular layer is formed, count the scale number having granular layer to be formed in every 100 scales, calculate every cell mean, relatively group difference, the results are shown in Table 1.
The impact that table 1 epigallocatechin gallate (EGCG) stearate gel is formed mouse tail scale granular layer of epidermis
Note: compare with Blank gel agent group, * P<0.05, * * P<0.01
From in upper table: compare with Normal group (see accompanying drawing 1), epigallocatechin gallate (EGCG) stearate gel is formed Mus tail scale granular layer of epidermis has obvious facilitation (see accompanying drawing 2), and middle and high dosage group is obviously better than marketed drug tretinoin cream (see accompanying drawing 3), show that epigallocatechin gallate (EGCG) stearate significantly can improve the Parakeratotic pathological state of psoriasis epidermis, the psoriatic medicine for the treatment of can be used as.
Embodiment 10
Epigallocatechin gallate (EGCG) stearate gel brings out the impact of psoriasis model on mice Propranolol.
Get body weight 20 ± 2g Kunming kind healthy mice 72, be divided into 6 groups at random, often organize male and female half and half, except Normal group, all the other mices are prepared Propranolol and bring out psoriasis model: with cotton swab uniform application 5% Propranolol Emulsion in left hard of hearing skin (the 0.3g/ ㎝ of every Mus
2), every twice-daily, smears 30 continuously, 24h after last coating, 6 groups often group randomly draw 2 mices (each 1 of male and female), get auricle modeling place skin, conventional sections observation, compares with Normal group, sets up with the Histological change such as parakeratosis, acanthosis decision model.
Modeling success mice 50, be divided into 5 groups at random, i.e. Blank gel agent group, three dose form nutgall catechin gallic acid ester stearate gels trial drug group (concentration is respectively 0.2%, 1.0%, 5.0%), tretinoin cream positive drug group (concentration is 0.025%), add Normal group totally 6 groups, often organize 10, male and female half and half.After this start administration, Normal group is coating not, and other is respectively organized evenly to be coated with respectively and gives corresponding medicine in mice modeling region, 0.1g/ Mus, every twice-daily, continuous coating 30 days; From modeling, day to coating completes the cosmetic variation that day every day observes mouse ear modeling place; After last coating, 24h puts to death animal, and get the left hard of hearing modeling place skin sample of mice immediately, fix by 10% formalin, paraffin embedding, section, HE dyes; Under optical microscope (× 400) one by one specimen observe the change such as horny layer, granular layer, prickle cell layer, basal cell layer, skin corium of skin, and the thickness of epidermis is measured with micrometer, be converted into actual (real) thickness (μm), calculate every cell mean, diversity between comparable group.
Result: perusal: modeling mice smeared 5% Propranolol Emulsion after 10 days, there is skin heating, redness, thicken and be covered with fine white squama in ear's modeling place local, modeling place skin heating when modeling completes, red and swollen, thicken and increase the weight of, alopecia, and be covered with more white squama, present severe psoriasis symptom; Be coated with medicine after 30 days, Blank gel agent group mice severe psoriasis Symptoms last, epigallocatechin gallate (EGCG) stearate gel group, the heating of tretinoin cream group mice coating place, red and swollen, thicken, cover the psoriasis symptoms such as squama and all alleviate or disappear; Period, the Normal group mice mental status was good, and skin of pinna is smooth, without red and swollen, thicken and cover with squama.
Mice Auricle dermal pathology is cut into slices in optical microphotograph Microscopic observation: Normal group is without parakeratosis, and Granulosa cells is flat, spine cell's break as, basal layer is made up of 1-2 confluent monolayer cells, skin corium NIP cell, tectology normal (see accompanying drawing 4); Visible horny layer fracture under modeling success mice mirror, granular layer is thinning or disappear, and parakeratosis is obvious, acanthosis, to be made up of multi-layer cellular, basal cell hyperplasia enlivens, and dermal inflammation cell more infiltration companion corium fabric, presents psoriasis pathology state (see accompanying drawing 5); Model mice is coated with after epigallocatechin gallate (EGCG) stearate gel, Granulosa cells significantly increases, epidermis cell parakeratosis and dermal inflammation cell obviously reduce, and prickle cell layer is thinning, and psoriasis symptom significantly alleviates or disappear (see accompanying drawing 6); Model mice is coated with after tretinoin cream, Granulosa cells increases not obvious, epidermis cell parakeratosis and dermal inflammation cell reduce to some extent, and psoriasis symptom alleviates to some extent, but effect is not as good as epigallocatechin gallate (EGCG) stearate gel group (see accompanying drawing 7).Each group of epidermal thickness measurement result is in table 2.
Table 2 epigallocatechin gallate (EGCG) stearate gel brings out the impact of psoriasis model epidermal thickness on mice Propranolol
| Group | To Mus amount (g/ amount) | Number of animals (only) | Epidermal thickness (μm) |
| Normal group | 0.0 | 10 | 17.13±2.53 |
| Blank gel agent group | 0.1 | 10 | 67.28±16.48 |
| 0.2%GTPS gel group | 0.1 | 10 | 49.85±12.34* |
| 1.0%GTPS gel group | 0.1 | 10 | 41.06±10.11** |
| 5.0%GTPS gel group | 0.1 | 10 | 32.25±8.26** |
| Tretinoin cream group | 0.1 | 10 | 42.69±10.65** |
Note: compare with Blank gel agent group, * P<0.05, * * P<0.01
Result shows: compare with Blank gel agent group, epigallocatechin gallate (EGCG) stearate gel can make Propranolol psoriasis model mouse skin generate heat, red and swollen, thicken, cover the psoriasis symptoms such as squama and significantly alleviate or disappear; By impelling, Propranolol psoriasis model mouse skin Granulosa cells significantly increases, cellular keratinization is complete and dermal inflammation cell obviously reduces, plump prickle cell layer is thinning thus make epidermis thinning, suppress the too fast and dyskeratosis of epidermal hyperplasia, make skin lesion be tending towards disappearing, significantly improve psoriatic pathological state; Instruction card nutgall catechin gallic acid ester stearate can be used as the psoriatic medicine for the treatment of.
Embodiment 11
Epigallocatechin gallate (EGCG) stearate gel causes the impact of effect of itching to Cavia porcellus histamine phosphate.
Get the cleaning grade healthy guinea pig 60 of body weight 250 ± 15g, be divided into 6 groups at random, i.e. Normal group, Blank gel agent group, three dose form nutgall catechin gallic acid ester stearate gels group (concentration is respectively 0.2%, 1.0%, 5.0%), tretinoin cream group (concentration is 0.025%), often organize 10, male and female half and half.Test first 2 days, shave hair to each group of right back instep of Cavia porcellus, area is 1cm × lcm; Normal group is coating not, and other is respectively organized to be coated with and gives corresponding medicine, 0.2g/ Mus, 2 times/d.Test the same day, shave hair place with the coarse sandpaper scratch right back instep of Cavia porcellus, make it rubescent, but with not hemorrhage for degree, local repastes medicine 1 time.10min after last administration, drip with 0.01% histamine phosphate at wound surface place microsyringe, 0.05ml/ foot, after this every 3min with 0.02%, 0.03%, 0.04% ... increase progressively histamine phosphate concentration, each 0.05ml/ foot, with occur Cavia porcellus later lick right back sufficient time the histamine phosphate total amount that gives for itch-threshold, as the observation index of antipruritic response strength.Record also respectively organizes itch-threshold, the results are shown in Table 3.
Table 3 epigallocatechin gallate (EGCG) stearate gel is on the impact of Cavia porcellus histamine phosphate itch-threshold effect
| Group | To Mus amount (g/ amount) | Number of animals (only) | Itch-threshold (μ g) |
| Normal group | 0.0 | 10 | 38.16±21.31 |
| Blank gel agent group | 0.2 | 10 | 40.35±18.24 |
| 0.2%GTPS gel group | 0.2 | 10 | 58.84±32.21* |
| 1.0%GTPS gel group | 0.2 | 10 | 216.33±99.59** |
| 5.0%GTPS gel group | 0.2 | 10 | 314.25±112.36** |
| Tretinoin cream group | 0.1 | 10 | 284.23±113.27** |
Note: compare with Normal group, * P<0.05, * * P<0.01
From in table 3: epigallocatechin gallate (EGCG) stearate gel can significantly improve the itch-threshold of histamine phosphate to Cavia porcellus, show that epigallocatechin gallate (EGCG) stearate has obvious itching-relieving action.
Embodiment 12
Epigallocatechin gallate (EGCG) stearate gel causes the impact of effect of itching to mice low molecular dextran-40
Get the healthy Kunming mouse 60 of body weight 20 ± 2g cleaning grade, be divided into 6 groups at random, i.e. Normal group, Blank gel agent group, three dose form nutgall catechin gallic acid ester stearate gels group (concentration is respectively 0.2%, 1.0%, 5.0%), tretinoin cream group (concentration is 0.025%), often organize 10, male and female half and half.The each group of right back dorsal portion of mice shaves hair, and area is 1cm × 1cm; Normal group is coating not, and other is respectively organized evenly to be coated with respectively and gives corresponding medicine in shaving territory, hair-fields, 0.1g/ Mus, 2 times/d, continuous 3d; 1h after last administration, each group of mouse tail vein injection 0.025% low molecular dextran-40, by 1.25mg/kg administration, to scratch head with mice fore paw, rear solid end is scratched trunk, mouth stings each position of whole body as pruritus indication, observes and records scabies and grab mice scabies in latent time, 30min and grab number of times and pruritus continues total time.The results are shown in Table 4.
Table 4 epigallocatechin gallate (EGCG) stearate gel causes the impact of effect of itching to low molecular dextran-40.
Note: compare with Normal group, * P<0.05, * * P<0.01
From in table: epigallocatechin gallate (EGCG) stearate gel energy significant prolongation low molecular dextran-40 causes mice scabies of itching and grabs latent time, reduce scabies and grab number of times, reduce pruritus and continue total time, high dose group is obviously better than positive control medicine, shows that epigallocatechin gallate (EGCG) stearate has obvious itching-relieving action.
It should be noted last that, above embodiment is only in order to illustrate technical scheme of the present invention and unrestricted, although with reference to preferred embodiment to invention has been detailed description, those of ordinary skill in the art is to be understood that, can modify to technical scheme of the present invention or equivalent replacement, and not departing from the spirit and scope of technical solution of the present invention, it all should be encompassed in the middle of right of the present invention.
Claims (2)
1. epigallocatechin gallate (EGCG) stearate application, is characterized in that, the application of described epigallocatechin gallate (EGCG) stearate in preparation treatment psoriasis.
2. the psoriatic pharmaceutical composition for the treatment of, it is characterized in that, described pharmaceutical composition is grouped into by the one-tenth of following weight percentage ratio: epigallocatechin gallate (EGCG) stearate 0.1% ~ 15%, carbomer940 0.5% ~ 2%, triethanolamine 0.7% ~ 3%, laurocapram 0.5% ~ 2%, dehydrated alcohol 5% ~ 40%, propylene glycol 5% ~ 15%, glycerol 5% ~ 15%, ethyl hydroxybenzoate 0.01 ~ 0.5%, surplus is purified water; Described pharmaceutical composition is prepared as follows: take each component by above-mentioned recipe quantity precision, get carbomer940 to be spread on and to boil and the purified water let cool is surperficial, swellingly to spend the night, obtain clear gel substrate, slowly adding triethanolamine under stirring makes substrate pH value be 7, for subsequent use; Get epigallocatechin gallate (EGCG) stearate, ethyl hydroxybenzoate is dissolved in dehydrated alcohol; Above-mentioned solution is transferred in gel-type vehicle for subsequent use, mix homogeneously, stirs 1h at water-bath 80 DEG C, add propylene glycol, glycerol, laurocapram successively, mix homogeneously, add purified water to 100%, stir, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310362217.2A CN103462987B (en) | 2013-08-19 | 2013-08-19 | The application of epigallocatechin gallate (EGCG) stearate and one treat psoriatic pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310362217.2A CN103462987B (en) | 2013-08-19 | 2013-08-19 | The application of epigallocatechin gallate (EGCG) stearate and one treat psoriatic pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103462987A CN103462987A (en) | 2013-12-25 |
| CN103462987B true CN103462987B (en) | 2015-11-18 |
Family
ID=49788185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310362217.2A Expired - Fee Related CN103462987B (en) | 2013-08-19 | 2013-08-19 | The application of epigallocatechin gallate (EGCG) stearate and one treat psoriatic pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103462987B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108272794A (en) * | 2018-01-17 | 2018-07-13 | 苏州大学 | The application of Epigallo-catechin gallate (EGCG) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1448395A (en) * | 2003-04-03 | 2003-10-15 | 浙江大学 | Antioxidant EGCG aliphatic ester and prep. thereof |
| CN101018554A (en) * | 2004-09-14 | 2007-08-15 | 味之素欧姆尼凯姆股份有限公司 | Topical compositions containing phosphorylated polyphenols |
| WO2012178127A2 (en) * | 2011-06-24 | 2012-12-27 | Liveleaf, Inc. | Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites |
-
2013
- 2013-08-19 CN CN201310362217.2A patent/CN103462987B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1448395A (en) * | 2003-04-03 | 2003-10-15 | 浙江大学 | Antioxidant EGCG aliphatic ester and prep. thereof |
| CN101018554A (en) * | 2004-09-14 | 2007-08-15 | 味之素欧姆尼凯姆股份有限公司 | Topical compositions containing phosphorylated polyphenols |
| WO2012178127A2 (en) * | 2011-06-24 | 2012-12-27 | Liveleaf, Inc. | Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites |
Non-Patent Citations (3)
| Title |
|---|
| 付华.茶多酚对牙周膜细胞的影响.《国际口腔医学杂志》.2009,第36卷(第5期),544-546、553. * |
| 田永强，等.凝胶剂中脂溶性茶多酚的含量测定.《江汉大学学报（自然科学版）》.2013,第41卷(第1期),93-95. * |
| 郑晓玲，等.儿茶凝胶的制备和抗炎药效学评价.《中国中药杂志》.2011,第36 卷(第18 期),2493-2497. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103462987A (en) | 2013-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109044915B (en) | Infant hip-protecting cream and preparation process thereof | |
| CN108553411B (en) | Azelaic acid gel and preparation method and application thereof | |
| CN107375437A (en) | A kind of anti acne of traditional Chinese medicine composition and its application | |
| CN104800269A (en) | Traditional Chinese medicine external-use cream used for treating psoriasis and preparation method thereof | |
| CN103479615B (en) | The application of epigallocatechin gallate (EGCG) cetylate and one treat psoriatic pharmaceutical composition | |
| CN103462987B (en) | The application of epigallocatechin gallate (EGCG) stearate and one treat psoriatic pharmaceutical composition | |
| CN104173607B (en) | It is a kind of to treat pharmaceutical composition of chloasma and preparation method thereof | |
| CN103463309B (en) | One treats psoriatic pharmaceutical composition | |
| CN103463308B (en) | The application of tea polyphenols stearate and one treat psoriatic pharmaceutical composition | |
| Kondziołka et al. | Overview of the Active Ingredients in Cosmetic Products for the Care of Skin That Has Been Exposed to Ionizing Radiation–Analysis of Their Effectiveness in Breast Cancer Radiotherapy | |
| CN104784297A (en) | Skin allergy prevention composition | |
| CN102716380A (en) | Compound acne-removal cream and production method thereof | |
| CN102423342B (en) | Medicinal composition for preventing and treating skin eczema and skin pruritus, formulation and application | |
| CN108403932A (en) | A kind of Chinese medicine compound prescription external preparation and its preparation method and application for treating steroid dependent dermatitis | |
| CN105796690B (en) | One kind treats psoriasic rose Chinese medicine composition and preparation method and application | |
| KR102368646B1 (en) | Atopy treatment lotion utilizing room temperature emulsifying process | |
| CN102274328B (en) | Medicament for treating psoriasis and preparation method thereof | |
| CN111840505A (en) | Traditional Chinese medicine preparation and plaster for treating psoriasis and preparation method thereof | |
| CN113274339A (en) | Silicone oil cream with itching relieving and moisture keeping effects and preparation method thereof | |
| CN105920003B (en) | A kind of external drug and preparation method thereof for treating psoriasis | |
| CN102697855A (en) | Medicinal composition for treating skin diseases | |
| CN114601787B (en) | Composite preparation, preparation method and application thereof | |
| US11607438B2 (en) | Topical cream-based cosmetic and wound healing formulations and methods of use | |
| CN108606985A (en) | It is a kind of to be used to treat compound salicylic acid lotion of Keratotic tinea hand or pedis and preparation method thereof | |
| CN105708750A (en) | Plant composition for improving keratosis pilaris as well as preparation method and applications of plant composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151118 Termination date: 20160819 |